肺癌患者血清趋化因子的表达水平及临床意义

摘要/Abstract

摘要： 【摘要】目的检测干扰素诱导的T细胞趋化因子（ITAC）、Fractalkine、巨噬细胞炎性蛋白（MIP）3α、白细胞介素8（IL8）、MIP1α和MIP1β在肺癌患者血清的表达水平，分析其与肺癌临床特征之间的关系及各趋化因子间相关性。方法采用液相芯片技术联合检测40例初诊肺癌患者和30例正常人血清中上述6种趋化因子的表达情况，采用SPSS 17.0软件分析其与肺癌临床特征的关系及各趋化因子之间的相关性。结果肺癌患者血清IL8、Fractalkine、MIP3α表达量中位数（四分位数间距）分别为5.16（4.74）、128.45(141.89)、10.31(8.88)，正常人分别为2.01（0.95）、61.46(74.81)、8.08(5.87)，组间差异均有统计学意义（Z=-4.783，P＜0.001；Z=-4.046，P＜0.001；Z=-3.105，P=0.002)。肺腺癌组MIP1β水平显著高于鳞状细胞癌组［18.32(12.27)∶13.72(7.31)，Z=-2.212，P=0.027］，而鳞状细胞癌组ITAC水平显著高于小细胞肺癌组［24.51(22.48)∶9.28(4.85)，Z=-2.460，P=0.014］；在肺癌患者和正常人中，MIP3α与Fractalkine均呈正相关（r=0.619，P＜0.001；r=0.766，P＜0.001）。结论IL8、Fractalkine、MIP3α在肺癌患者中的表达明显升高，可能在肺癌的转移中发挥重要作用。

关键词: 肺肿瘤, 趋化因子类, 受体, 趋化因子

Abstract: 【Abstract】ObjectiveTo detect the expression levels of multiple serum chemokines including IFNinducible T cell chemoattractant (ITAC), Fractalkine, macrophage inflammatory protein(MIP)3α, IL8, MIP1α, MIP1β in patients with lung cancer and explore their association with the clinical characteristics of lung cancer as well as the correlations among these chemokines. MethodsForty newly diagnosed patients with lung cancer and thirty healthy controls were enrolled for detection of the serum levels of 6 kinds of chemokines by Luminex technology. The correlations of clinical characteristics of lung cancer with these chemokines and the correlations among these chemokines were analyzed by SPSS 17.0 software. ResultsThe serum levels ［M(QR)］ of IL8, Fractalkine and MIP3α in patients with lung cancer were 5.16（4.74）, 128.45(141.89), 10.31(8.88) respectively, and 2.01（0.95）, 61.46(74.81), 8.08(5.87) respectively in control group, with significant differences (Z=-4.783, P＜0.001; Z=-4.046, P＜0.001; Z=-3.105, P=0.002). The expression of MIP1β in lung adenocarcinoma was significantly higher than that in squamous carcinoma ［18.32(12.27) vs. 13.72(7.31), Z=-2.212, P=0.027］, and of ITAC in squamous carcinoma was significantly higher than that in small cell lung cancer ［24.51(22.48) vs. 9.28(4.85), Z=-2.460, P=0.014］. The expressions of MIP3α and Fractalkine were positively correlated in the two groups (r=0.619, P＜0.001; r=0.766, P＜0.001). ConclusionThe expressions of IL8, Fractalkine and MIP3α increase significantly in lung cancer patients, and they are may play important roles in metastatic lung cancer.

Key words: Lung neoplasms, Chemotactic factors, Receptors, chemokine

王菀菀, 孙俊宁, 操珍, 李海燕, 苏文. 肺癌患者血清趋化因子的表达水平及临床意义[J]. 国际肿瘤学杂志, 2016, 43(2): 90-.

WANG Wan-Wan, SUN Jun-Ning, CAO Zhen, LI Hai-Yan, SU Wen. Expression and clinical significance of serum chemokines in patients with lung cancer[J]. Journal of International Oncology, 2016, 43(2): 90-.

参考文献

［1］ Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012［J］. CA Cancer J Clin, 2015, 65(2): 87108. DOI:10.3322/caac.21262. ［2］ Luppi F, Longo AM, De Boer WI, et al. Interleukin8 stimulates cell proliferation in nonsmall cell lung cancer through epidermal growth factor receptor transactivation［J］. Lung Cancer, 2006, 56(1): 2533. ［3］ Zhu YM, Webster SJ, Flower D, et al. Interleukin8/CXCL8 is a growth factor for human lung cancer cells［J］. Br J Cancer, 2004, 91(11): 19701976. ［4］ Sanmamed MF, CarranzaRua O, Alfaro C, et al. Serum interleukin8 reflects tumor burden and treatment response across malignancies of multiple tissue origins［J］. Clin Cancer Res, 2014, 20(22): 56975707. DOI:10.1158/10780432.CCR133203. ［5］ Song XY, Zhou SJ, Xiao N, et al. Research on the relationship between serum levels of inflammatory cytokines and nonsmall cell lung cancer［J］. Asian Pac J Cancer Prev, 2013, 14(8): 47654768. ［6］ Liu Z, Xu S, Xiao N, et al. Overexpression of IL8 and MMP9 confer high malignant phenotype in patients with nonsmall cell lung cancer［J］. Zhongguo Fei Ai Za Zhi, 2010, 13(8): 795802. DOI:10.3779/j.issn.10093419.2010.08.09. ［7］ Lee LF, Hellendall RP, Wang Y, et al. IL8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration［J］. J Immunol, 2000, 164(5): 27692775. ［8］ Park MH, Lee JS, Yoon JH. High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumorinfiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma［J］. J Surg Oncol, 2012, 106(4): 386392. DOI:10.1002/jso.23095. ［9］ Ohta M, Tanaka F, Yamaguchi H, et al. The high expression of Fractalkine results in a better prognosis for colorectal cancer patients［J］. Int J Oncol, 2005, 26(1): 4147. ［10］ Hyakudomi M, Matsubara T, Hyakudomi RA, et al. Increased expression of Fractalkine is correlated with a better prognosis and an increased number of both CD8(+) T cells and natural killer cells in gastric adenocarcinoma［J］. Ann Surg Oncol, 2008, 15(6): 17751782. DOI:10.1245/s1043400898763. ［11］ Jy K, Arita Y, Shinohara K, et al. Antitumor immune activity by chemokine CX3CL1 in an orthotopic implantation of lung cancer model in vivo［J］. Mol Clin Oncol, 2013, 1(1): 3540. ［12］Ren T, Chen QF, Tian ZG, et al. Downregulation of surface fractalkine by RNA interference in B16 melanoma reduced tumor growth in mice［J］. Biochem Biophys Res Commun, 2007, 364(4): 978984. DOI:10.1016/j.bbrc.2007.10.124. ［13］Kirshberg S, Izhar U, Amir G, et al. Involvement of CCR6/CCL20/IL17 axis in NSCLC disease progression［J］. PLoS One, 2011, 6(9): e24856. DOI:10.1371/journal.pone.0024856. ［14］Yamauchi K, Akbar SM, Horiike N, et al. Increased serum levels of macrophage inflammatory protein3 alpha in hepatocellular carcinoma: Relationship with clinical factors and prognostic importance during therapy［J］. Int J Mol Med, 2003, 11(5): 601605. ［15］Cai Y, Li J, Lu A, et al. Increased serum levels of macrophage inflammatory protein3α and cystatin a predict a poor prognosis of nasopharyngeal carcinoma［J］. Medicine (Baltimore), 2014, 93(22): e123. DOI:10.1097/MD.0000000000000123. ［16］Iwata T, Tanaka K, Inoue Y, et al. Macrophage inflammatory protein3 alpha (MIP3a) is a novel serum prognostic marker in patients with colorectal cancer［J］. J Surg Oncol, 2013, 107(2): 160166. DOI:10.1002/jso.23247. ［17］Zhang XP, Meng AH, Wang HE, et al. High serum macrophage inflammatory protein3α is associated with the early recurrence or metastasis of nonsmall cell lung cancer following primary pulmonary resection［J］. Oncol Lett, 2014, 8(2): 948952. DOI:10.3892/ol.2014.2229. ［18］Kanegasaki S, Tsuchiya T. Alarmins released during local antitumor treatments play an essential role in enhancing tumor growth inhibition at treated and nontreated sites via a derivative of CCL3［J］. Oncoimmunology, 2014, 3(10): e958956. ［19］He S, Wang L, Wu Y, et al. CCL3 and CCL20recruited dendritic cells modified by melanoma antigen gene1 induce antitumor immunity against gastric cancer ex vivo and in vivo［J］. J Exp Clin Cancer Res, 2010, 29(1): 37. DOI:10.1186/175699662937. ［20］Luo X, Yu Y, Liang A, et al. Intratumoral expression of MIP1beta induces antitumor responses in a preestablished tumor model throughchemoattracting T cells and NK cells［J］. Cell Mol Immunol, 2004, 1(3): 199204. ［21］Sadeghi M, Lahdou I, Oweira H, et al. Serum levels of chemokines CCL4 and CCL5 in cirrhotic patients indicate the presence of hepatocellularcarcinoma［J］. Br J Cancer, 2015, 113(5): 756762. DOI:10.1038/bjc.2015.227. ［22］Chu Y, Yang X, Xu W, et al. In situ expression of IFNgammainducible T cell alpha chemoattractant in breast cancer mounts an enhanced specific antitumor immunity which leads to tumor regression［J］. Cancer Immunol Immunother, 2007, 56(10): 15391549. DOI:10.1007/s0026200702961.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[3]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[4]	贺嘉慧, 胡钦勇. 基于GBD数据的中国和美国肺癌发病和死亡趋势及危险因素对比分析[J]. 国际肿瘤学杂志, 2024, 51(1): 29-36.
[5]	冯诚天, 黄芙蓉, 曹世玉, 王健宇, 南丁阿比雅思, 姜永冬, 朱娟英. HER2阳性乳腺癌患者HER2表达水平与影像学特征的关系[J]. 国际肿瘤学杂志, 2023, 50(9): 527-531.
[6]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[7]	王文德, 曾德. 乳腺癌内分泌治疗耐药的机制研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 352-356.
[8]	张丽, 向卓, 王强, 毕经旺. CAR-T免疫治疗相关的细胞因子释放综合征研究进展[J]. 国际肿瘤学杂志, 2023, 50(6): 377-381.
[9]	丁浩, 应劲涛, 付茂勇. CAR-T在食管鳞状细胞癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 231-235.
[10]	朱军, 黄美金, 李媛, 刘泽刚, 荀欣, 陈宏. HER2低表达乳腺癌的靶向治疗研究进展[J]. 国际肿瘤学杂志, 2023, 50(4): 236-240.
[11]	李佳璇, 封颖璐. 糖皮质激素受体在肝癌细胞生长中的作用机制[J]. 国际肿瘤学杂志, 2023, 50(4): 241-243.
[12]	李雄安, 颜艳艳. 丙戊酸镁用于治疗继发癫痫的晚期肺癌脑转移患者1例报道[J]. 国际肿瘤学杂志, 2023, 50(3): 191-192.
[13]	宁婷婷, 胡钦勇, 李倩, 杨鹏程. 奥希替尼与埃克替尼一线治疗EGFR阳性转移性NSCLC临床疗效观察[J]. 国际肿瘤学杂志, 2023, 50(2): 65-70.
[14]	张碧霞, 丁江华. EGFR突变型非小细胞肺癌EGFR-TKI获得性耐药后免疫治疗现状[J]. 国际肿瘤学杂志, 2023, 50(2): 97-101.
[15]	左小平, 刘晓川, 吴西强, 李周, 夏天, 刘国凤. 老年早期肺癌患者经胸腔镜肺切除术后心律失常发生的危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2023, 50(12): 711-716.